HolderBook

TRAVERE THERAPEUTICS INC (TVTX)

Institutional ownership reported to the SEC as of Q3 2026, across 24 quarters.

8
Reporting holders
$6.1M
Reported value
0.0%
Calls
0.0%
Puts
-315
Holder change

Calls and puts are the parts of reported value carried in derivative lines rather than shares, and they point in opposite directions: a manager holding calls is positioned for the security, one holding puts against it - or hedging shares they already own, which is why index funds carry so many. Most sites add the two together and report one figure, which averages away the only interesting part.

Holders

Download these holders as CSV

FilerValueShares Their book Held Change
Insight Wealth Strategies, LLC$5.7M96,6770.56%newNEW
Farther Finance Advisors, LLC$233.5K3,9660.00%12q+1217.6%+$215.8K
GAMMA Investing LLC$76.7K1,3030.00%11q+115.0%+$41.0K
Versant Capital Management, Inc$37.3K6330.00%8q+3.6%+$1.3K
EASTERN BANK$19.1K3250.00%3qHELD
MassMutual Private Wealth & Trust, FSB$15.4K2610.00%12q+7.0%+$1.0K
CoreCap Advisors, LLC$1.2K210.00%4qHELD
TOTH FINANCIAL ADVISORY CORP$29550.00%newNEW

Five percent filings

Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →

FiledFormFiler % of class
2026-08-1413G/AArmistice Capital, LLCwith 1 co-filers1.7%
2026-08-1213GBANK OF AMERICA CORP /DE/5.8%
2026-08-0713GSTATE STREET CORPORATION4.6%
2026-08-0613G/AFMR LLCwith 1 co-filers7.7%

What the company announced

Form 8-K filings from the last 120 days, showing only the items worth a reader's attention. Earnings releases, exhibit attachments and general disclosures are filed constantly and are left out. Filed is when the SEC received it; event is the date the company says the thing happened.

FiledEvent dateWhatSource
2026-09-212026-09-21Directors or officers departed or appointedfiling

What the insiders did

Open market purchases and sales reported on Form 4 in the last 180 days. Grants, option exercises and shares surrendered to cover tax are left out: they are compensation rather than a decision to buy or sell. Where a broker filled one order in tranches the lines are summed, because it was one decision.

Officers and directors

DateInsiderRoleSideSharesValue
2026-09-16Dube Eric MCHIEF EXECUTIVE OFFICERSold195,841$12.4M ×2
2026-09-16Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSold172,717$11.0M ×2
2026-09-16ROTE WILLIAM E.Chief Research OfficerSold112,850$7.1M ×2
2026-09-17Dube Eric MCHIEF EXECUTIVE OFFICERSold108,493$7.0M ×2
2026-09-15Heerma PeterEVP, CHIEF COMMERCIAL OFFICERSold102,190$6.4M ×4
2026-09-15ROTE WILLIAM E.Chief Research OfficerSold96,198$6.0M ×4
2026-09-15Dube Eric MCHIEF EXECUTIVE OFFICERSold95,666$6.0M ×4
2026-09-15Cline Christopher R.CHIEF FINANCIAL OFFICERSold50,508$3.1M ×4
2026-09-15Inrig JulaEVP, Head of R&D & CMOSold44,674$2.8M ×4
2026-04-15Dube Eric MCHIEF EXECUTIVE OFFICERSold64,000$2.6M ×3
2026-09-15REED ELIZABETH EChief Legal Officer and GCSold37,500$2.3M ×4
2026-09-10Meckler Jeffrey ADirectorSold20,000$1.3M ×4

Quarter by quarter

Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.

QuarterHoldersValue SharesNewAdded TrimmedOptions
Q3 20268$6.1M103,1912400.0%
Q2 2026323$6.5B111,237,64991120852.2%
Q1 2026267$3.2B102,505,0624390894.6%
Q4 2025286$4.2B103,162,7716988965.2%
Q3 2025247$2.6B102,601,3195773814.4%
Q2 2025219$1.5B100,819,7704372702.6%
Q1 2025221$1.8B98,238,2544487542.2%
Q4 2024200$1.7B95,258,0304374512.3%
Q3 2024179$1.2B83,659,9772961582.3%
Q2 2024172$736.4M88,912,5082769470.8%
Q1 2024174$742.9M95,304,4283063461.0%
Q4 2023168$830.8M90,336,5342656482.2%
Q3 2023175$773.2M82,620,7633764474.5%
Q2 2023170$1.3B82,872,0602983370.9%
Q1 2023176$1.9B84,471,4043681300.6%
Q4 2022156$1.5B73,000,7101369490.2%
Q3 2022170$1.8B73,940,2402362530.6%
Q2 2022170$1.7B69,745,1982151630.4%
Q1 2022173$1.8B70,057,4662359580.4%
Q4 2021174$2.1B67,827,6523549470.7%
Q3 2021150$1.5B60,891,5543340520.8%
Q2 2021137$934.3M63,264,2252351410.5%
Q1 2021151$1.6B62,635,3573855370.4%
Q4 2020142$1.4B52,325,684140000.9%